Houston、TXにおける胃癌の臨床試験
Houstonとその周辺地域（約30マイル以内）の拠点で、胃癌に関する42件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
被験者募集中第2相
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- UT MD Anderson Cancer Center, Houston
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
被験者募集中第2相
- The University of Texas MD Anderson Cancer Center, Houston
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
被験者募集中第2相
- Research Site, Houston
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
被験者募集中第2/3相
- University of Texas MD Anderson Cancer Center, Houston
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
被験者募集中第3相
- MD Anderson Cancer Center, Houston
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
被験者募集中第2相
- Research Site, Houston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
被験者募集中第1相
- MD Anderson Cancer Center, Houston
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
被験者募集中第1相
- Baylor College of Medicine, Houston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
被験者募集中第1/2相
- MD Anderson, Houston
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
被験者募集中第1/2相
- MD Anderson Cancer Center, Houston
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- The University of Texas MD Anderson Cancer Center, Houston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
被験者募集中第1相
- Oncology Consultants, Houston
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
被験者募集中第3相
- Research Site, Houston
A Phase 1/1b Study of IAM1363 in HER2 Cancers
被験者募集中第1相
- MD Anderson Cancer Center - University of Texas, Houston
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
被験者募集中第1相
- UT MD Anderson Cancer Center, Houston
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
被験者募集中第1/2相
- The University of Texas MD Anderson Cancer Center, Houston
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- Research Site, Houston
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
被験者募集中第1相
- MD Anderson Cancer Center, Houston
A Study of MGC026 in Participants With Advanced Solid Tumors
被験者募集中第1相
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- The University of Texas, MD Anderson Cancer Center, Houston
IDOV-Immune for Advanced Solid Tumors
被験者募集中第1相
- MD Anderson Cancer Center, Houston
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- Oncology Consultants, Houston
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Investigative Site #129, Houston
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
被験者募集中第1相
- The University of Texas MD Anderson Cancer Center Investigational Pharmacy Services, Houston
- The University of Texas MD Anderson Cancer Center, Houston
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
被験者募集中第1相
- The University of Texas MD Anderson Cancer Center, Houston
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
被験者募集中第2相
- MD Anderson Cancer Center, Houston
Lead-212 PSV359 Therapy for Patients With Solid Tumors
被験者募集中第1/2相
- MD Anderson Cancer Center, Houston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
被験者募集中第1相
- Oncology Consultants, PA, Houston
- Oncology Consultants, PA., Houston
- The University of Texas M.D. Anderson Cancer Center, Houston
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
被験者募集中第1相
- The University of Texas MD Anderson Cancer Center /ID# 270059, Houston
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
被験者募集中第1相
- The University of Texas MD Anderson Cancer Center, Houston
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
被験者募集中第1相
- MD Anderson Cancer Center, Houston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- MD Anderson Cancer Center, Houston
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
被験者募集中第2相
- M D Anderson Cancer Center, Houston
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
被験者募集中第1/2相
- MD Anderson Cancer Center, Houston
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
被験者募集中第3相
- The University of Texas MD Anderson cancer Center, Houston
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
被験者募集中第1相
- Baylor St. Luke's Medical Center, Houston
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
被験者募集中第1/2相
- The University of Texas MD Anderson Cancer Center, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Houston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
被験者募集中第1/2相
- MD Anderson Cancer Center, Houston
A Study of NX-1607 in Adults With Advanced Malignancies
被験者募集中第1相
- MD Anderson Cancer Center, Houston
Comprehensive Outcomes for After Cancer Health
被験者募集中健康なボランティア歓迎
- The University of Texas MD Anderson Cancer Center, Houston
- UT Health Houston, Houston
他の都市における胃癌の試験
- Boston, MA32件の研究
- New York City, NY31件の研究
- Nashville, TN28件の研究
- Baldwin Park, CA22件の研究
- Los Angeles, CA22件の研究
- Arlington, VA20件の研究
- Dallas, TX19件の研究
- San Antonio, TX19件の研究
- St. Louis, MO18件の研究
- Grand Rapids, MI18件の研究
- Washington, DC16件の研究
- Chicago, IL16件の研究
Houstonにおける他の研究
- 非小細胞肺癌145件の研究
- 乳がん126件の研究
- がん（全種類）121件の研究
- 転移性癌104件の研究
- 大腸癌102件の研究
- 卵巣がん89件の研究
- 急性骨髄性白血病85件の研究
- 肺がん78件の研究
- 前立腺がん76件の研究
- 子宮内膜がん68件の研究
- 膵臓がん61件の研究
- 悪性黒色腫59件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。